Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Activating mutations in NRAS account for 20%-30% of melanoma, but despite decades of research and in contrast to BRAF, no effective anti-NRAS therapies have been forthcoming. Here, we identify a previously uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. STK19 phosphorylates NRAS to enhance its binding to its downstream effectors and promotes oncogenic NRAS-mediated melanocyte malignant transformation. A recurrent D89N substitution in STK19 whose alterations were identified in 25% of human melanomas represents a gain-of-function mutation that interacts better with NRAS to enhance melanocyte transformation. STK19D89N knockin leads to skin hyperpigmentation and promotes NRASQ61R-driven melanomagenesis in vivo. Finally, we developed ZT-12-037-01 (1a) as a specific STK19-targeted inhibitor and showed that it effectively blocks oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo. Together, our findings provide a new and viable therapeutic strategy for melanomas harboring NRAS mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 5×
“Analysis of STK19 alteration in melanomas collected in different cBioPortal for Cancer Genomics databases further confirmed this discovery (Barretina et al., 2012; Hodis et al., 2012; Hugo et al., 2016).”
InfluentialSelf-citationA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“The RAS family has three major isoforms, KRAS, HRAS and NRAS (Barbacid, 1987; Malumbres and Barbacid, 2003) that share 92-98% sequence identity in their amino-terminal region, and oncogenic mutations of RAS family members are commonly found in 20% to 30% of all human tumors (Prior et al., 2012; Stephen et al., 2014).”
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“However, unlike the well-defined inhibitors targeting the oncogenic BRAF mutation (Lavoie and Therrien, 2015), the development of NRAS-selective inhibitors has been unsuccessful in the past decades (Cox et al., 2014).”
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Cited by
A Genetic Map of the Response to DNA Damage in Human Cells
Olivieri, M., Cho, T., Álvarez-Quilón, A., Li, K., Schellenberg, M. J., Zimmermann, M., Hustedt, N., Rossi, S. E., Adam, S., Melo, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.040 · Cited by 551
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Rambow, F., Marine, J.-C., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 325
Self-citationRAS: Striking at the Core of the Oncogenic Circuitry
Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174
“Pharmacologic inhibitors of STK19 blocked NRAS phosphorylation and impaired melanoma cell growth and tumor formation capacity, and extended survival of tumor-bearing mice (126).”
BackgroundGenes and Pseudogenes: Complexity of the RCCX Locus and Disease
Carrozza, C., Foca, L., De Paolis, E., & Concolino, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.709758 · Cited by 37
Tan, Y., Gao, M., Huang, Y., Zhan, D., Wu, S., An, J., Zhang, X., & Hu, J. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae787 · Cited by 31
Jandova, J., & Wondrak, G. T. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.10.007 · Cited by 20
Metadata
- Authors
- Yin, C., Zhu, B., Zhang, T., Liu, T., Chen, S., Liu, Y., Li, X., Miao, X., Li, S., Mi, X., Zhang, J., Li, L., Wei, G., Xu, Z.-X., Gao, X., Huang, C., Wei, Z., Goding, C. R., Wang, P., Deng, X., & Cui, R.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 176
- Issue
- 5
- Pages
- 1113-1127.e16
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2912706099
- Cited by
- 94
- References
- 26
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.